What have pharmacies paid for Spinosad since 2013?
What pharmacies pay, not what you pay. Spinosad has 1 product in the CMS NADAC survey, 1 product with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged. Spinosad 0.9% Topical Susp: $1.53 per unit at the 2013 survey and $2.01 at 2026 (+32%, thin).
Not medical or financial advice. This page reports what pharmacies pay to acquire a drug, from the CMS NADAC survey. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.
Spinosad1 product in NADAC
1product with a price history
Spinosad has 1 product in the CMS NADAC survey, 1 product with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged.
1 of the changes rest on fewer than 3 priced NDCs at one end and are marked thin: a median over one or two NDCs reflects which NDCs were priced as much as a price movement.
This is a per-unit acquisition cost, not a retail price, a copay or an insurer's price, and it says nothing about why a price moved.
Spinosad 0.9% Topical Susp
Generic
$1.53 per mL at the 2013 year-end survey (1 NDC) and $2.01 at the 2026 survey (3 NDCs): +32%, a thin comparison.
year-end median across the NDCs pricedlowest to highest NDC
Year-end survey
Median per mL
Lowest to highest
NDCs priced
2013 (2013-12-25)
$1.53
1
2014 (2014-12-31)
$1.64
2
2015 (2015-12-30)
$1.63
2
2016 (2016-12-28)
$1.81
2
2017 (2017-12-27)
$1.60
1
2025 (2025-12-31)
$1.88
2
2026 (2026-11-11)
$2.01
3
CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.
How many companies make Spinosad?
The FDA Orange Book lists no generic maker as marketed for Spinosad. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.